Focuses on precision oncology medicines to treat patients with genetically defined cancers.
Black Diamond Therapeutics, Inc. is a pioneering biotechnology firm dedicated to discovering, developing, and commercializing medicines tailored for patients with genetically defined tumors. Central to its innovative approach is the development of BDTX-189, an irreversible small molecule inhibitor meticulously engineered to target oncogenic proteins associated with non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations.
In addition to BDTX-189, Black Diamond Therapeutics, Inc. is advancing other promising candidates such as BDTX-1535, a brain-penetrant inhibitor designed to counteract EGFR mutations, encompassing canonical, intrinsic resistance, and acquired resistance mutations. Furthermore, the company is developing BDTX-4933, another brain-penetrant inhibitor aimed at oncogenic BRAF class I, II, and III alterations, further expanding its therapeutic portfolio.
Founded in 2014 under the name ASET Therapeutics, Inc., the company rebranded as Black Diamond Therapeutics, Inc. in January 2018. Headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics, Inc. thrives on its strategic partnership with OpenEye Scientific Software, Inc., leveraging cutting-edge technologies and innovative strategies to address critical unmet needs in oncology.